Forbes Study: E-cigarette is Better Aid for Quitting Smoking

Industry Insight by 2FIRSTS.ai
Apr.01.2024
Forbes Study: E-cigarette is Better Aid for Quitting Smoking
E-cigarettes more effective in helping smokers quit than traditional methods, according to recent study in emergency medical journal.

According to the latest report from Forbes, e-cigarettes can help people quit smoking, even more successfully than traditional methods like nicotine patches. Recent experimental results published in an emergency medical journal show that among nearly 1000 smokers waiting in the emergency rooms of six hospitals in the UK, those who were given e-cigarettes were more likely to successfully quit smoking compared to those who only received written guidance for quitting. The success rate of those who received e-cigarettes was 76% higher.

 

According to a recent study published in the Emergency Medicine Journal, individuals who were provided with free e-cigarettes were more likely to quit smoking compared to those who only received paper promotional materials. The study, which involved nearly 1000 smokers in the emergency rooms of six hospitals in the UK, found that those who received e-cigarettes had a 76% higher likelihood of quitting smoking.

 

In addition to providing e-cigarette starter kits, researchers also offered smoking cessation advice to participants and guided them to local "quit smoking services." As a control group, some individuals only received written recommendations about local "quit smoking services." The study results showed that six months later, nearly a quarter of those who received e-cigarettes reported that they had quit smoking, which was significantly higher compared to the 13% in the control group.

 

Research findings further demonstrate that even among individuals who use e-cigarettes but have not quit smoking, they still have a higher likelihood of trying to quit smoking compared to the control group. Their daily cigarette consumption is also lower than when they initially started using e-cigarettes. The final cessation rates for both groups are relatively low, with a cessation rate of 7.2% for those who use e-cigarettes and 4.1% for the control group, as confirmed by carbon monoxide breath tests.

 

Although e-cigarettes pose certain risks, they are much less harmful compared to smoking tobacco. Caitlin Notley, a research fellow at the University of East Anglia and one of the study's lead authors, stated in a press release, "We know that e-cigarettes are far less harmful than smoking tobacco, and they have been shown to help smokers quit.

 

Another researcher from the University of East Anglia, Ian Pope, stated: "In 2019, smoking caused nearly 75,000 deaths in the UK, making it the leading cause of preventable deaths and diseases in the country. Switching to e-cigarettes could save thousands of lives." The team believes that if their plan is widely implemented, it could help over 22,000 people successfully quit smoking every year.

 

In addition to supporting the use of e-cigarettes as a smoking cessation tool, the trial also demonstrated the possibility of conducting interventions in hospital emergency departments. Pop said, "The emergency department provides an opportunity to reach those who may not have the motivation to quit smoking, or may lack the knowledge or resources to access 'quit smoking services'." Most participants in the trial lived in impoverished areas, where more people are unemployed or unable to work due to illness or disability, so this approach could potentially help more disadvantaged communities."

 

Lion Shahab, co-director of the Tobacco and Alcohol Research Group at University College London, praised the study, describing it as a way to achieve "brief interventions" that can be easily implemented within existing healthcare services to make use of waiting times. The researcher, who was not involved in the trial, stated in a press release that this approach could have a positive impact on reducing health inequalities.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24